Talk to us
An example

What a family gets

Every family gets a workspace built from the patient's own records and tumor sequencing. It shows where things stand, the options that fit, and how to get each one. Here it is with two made-up patients.

Pick the situation closer to yours. Both patients are invented, and nothing here is advice for a real case.

Example workspace Made-up patient and record
Colorectal cancer, spread to the liver

What we can do now, and in what order.

The cancer grew on second-line chemotherapy. Sequencing found a KRAS G12C mutation, and two approved drug combinations target it directly. Every other option is mapped behind them, each with how to get it.

3things need a decision or a booking

At a glance

The facts that decide what comes next.

Time since diagnosis
2 yearsfound on colonoscopy, liver spots at diagnosis
Treatment so far
2 linesFOLFOX, then FOLFIRI, both with bevacizumab
What sequencing found
KRAS G12Cmicrosatellite stable, HER2 not amplified
Where it stands
Growingtwo liver spots larger on the last scan

What needs attention first

This week

Choose the next treatment

The two KRAS G12C combinations are close. The oncologist and family pick one, using the comparison prepared in the workspace.

Within 2 weeks

Book the baseline scan

A CT before the new drug starts, so the next scan can show whether it is working.

Ready when needed

Trial screening questions

Eligibility for three matched trials is already worked out, so a switch does not start from zero.

Every option, ranked

Ordered by the strength of the evidence for this tumor, not by how new an option sounds.

  1. 1
    Available now

    Adagrasib with cetuximab

    FDA-approved for KRAS G12C colorectal cancer after the chemotherapy this patient has had.

    How you get itThe oncologist prescribes it on label. The mutation is already confirmed in the sequencing report.

  2. 2
    Available now

    Sotorasib with panitumumab

    Approved for the same setting. Kept side by side with option 1 so the choice is made on dosing, side effects, and schedule.

    How you get itSame as option 1. Insurance prior authorization is drafted and ready to send.

  3. 3
    Screen now

    Trials of newer KRAS G12C drugs

    Three open trials match this tumor and prior treatment, two within driving distance.

    How you get itWe prepare the eligibility answers and contact the trial sites with the oncologist's approval.

  4. 4
    Later

    Other approved options for this stage

    Trifluridine and tipiracil with bevacizumab, fruquintinib, and regorafenib. Mapped now so they are ready if they are needed.

    How you get itStandard prescriptions through the oncology clinic. No extra paperwork expected.

Not ranked: immunotherapy on its own. This tumor is microsatellite stable, and the evidence says it is unlikely to help.

What we keep watching

Each item has the event that would make it matter, and what happens then.

If this happensThen
A matched trial opens a site closer to homeThe family hears about it that week
New results for KRAS G12C drugs are publishedThe ranking above is re-checked
The first scan on the new treatment comes backIt is compared with the baseline and the next step is set

Every option links to its evidence in a real workspace. The ranking is reviewed by experts who have read the whole record.

For a real case

Your workspace is built from your own record.

From your records

We start from the sequencing report and the medical records you already have, and say plainly if more testing would help.

Checked by people

Software finds and grades the options. Experts who read the whole record decide what fits and in what order.

Kept current

New trials and new evidence are checked as they appear, for as long as we are working on the case.

Get in touch

Tell us about your case and we will show you what yours would look like.

A few lines is enough to start.

Talk to us about your case